Table 1.

Summary measures for the considered clinical and demographic characteristics.

Characteristic	N	Summary Measure
CCP score, median (IQR)	141	0.12 (−0.43, 0.66)
Age, years at diagnosis, median (IQR)	141	66 (60, 71)
Ethnicity† (%)
African-American	81	57.4
Other	60	42.6
Baseline PSA‡ (ng/ml), median (IQR)	140	8.04 (5.45, 13.47)
Clinical stage (%)
T1	72	60.0
T2	44	36.7
T3	4	3.3
Gleason score (%)
<7	54	38.3
7	70	49.6
>7	17	12.1
Concurrent hormone use (%)
No	74	52.5
Yes	67	47.5
Percent positive cores, median (IQR)	134	45 (24, 67)
Year of biopsy, median (IQR)	141	2004 (2001, 2005)
Modified D’Amico risk (%)
Low	38	27.3
Intermediate	72	51.8
High	29	20.9
Radiation Dose (Gy), median (IQR)	116	74 (71, 74)

Abbreviations: CCP = cell cycle progression; IQR = interquartile range; PSA = prostate-specific antigen; Gy = gray.

^†Data were collected upon 81 African-Americans, 58 Whites, and 2 patients of “Other” ethnicity. We dichotomized ethnicity, to avoid statistical modeling issues resulting from data sparseness.

^‡Maximum baseline PSA was 87.7 ng/ml.